Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes

Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus...

Descripción completa

Detalles Bibliográficos
Autores principales: El Ghali, Amer, Morrisette, Taylor, Alosaimy, Sara, Lucas, Kristen, Tupayachi-Ortiz, Maria G., Vemula, Raaga, Wadle, Carly, Philley, Julie V., Mejia-Chew, Carlos, Hamad, Yasir, Stevens, Ryan W., Zeuli, John D., Webb, Andrew J., Fiske, Christina T., Simonyan, Anahit, Cimino, Christo L., Mammadova, Mehriban, Umana, Virginia E., Hasbun, Rodrigo, Butt, Saira, Molina, Kyle C., Thomas, Michael, Kaip, Emily A., Bouchard, Jeannette, Gore, Tristan W., Howard, Catessa, Cabanilla, M. Gabriela, Holger, Dana J., Frens, Jeremy J., Barger, Melissa, Ong, Aaron, Cohen, Keira A., Rybak, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583686/
https://www.ncbi.nlm.nih.gov/pubmed/37768312
http://dx.doi.org/10.1128/aac.00824-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583686/
https://www.ncbi.nlm.nih.gov/pubmed/37768312
http://dx.doi.org/10.1128/aac.00824-23

Ejemplares similares